Showing 1 - 3 results of 3 for search 'Sareh Seyedkazemi', query time: 0.02s Refine Results
  1. 1
    Low Incidence and Brief Duration of Gastrointestinal Adverse Events with Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Over 96 Weeks: Post hoc Analyses of AMBER and EMERALD

    Low Incidence and Brief Duration of Gastrointestinal Adverse Events with Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Over 96 Weeks: Post hoc Analyses of AM... by Keith Dunn, Bryan Baugh, Nika Bejou, Donghan Luo, Jennifer Campbell, Sareh Seyedkazemi, David Anderson

    Published 2022-04-01
    Get full text
    Article
  2. 2
    Pooled resistance analyses of darunavir once-daily regimens and formulations across 10 clinical studies of treatment-naïve and treatment-experienced patients with human immunodeficiency virus-1 infection

    Pooled resistance analyses of darunavir once-daily regimens and formulations across 10 clinical studies of treatment-naïve and treatment-experienced patients with human immunodefic... by Erkki Lathouwers, Sareh Seyedkazemi, Donghan Luo, Kimberley Brown, Sandra De Meyer, Eric Y. Wong

    Published 2020-07-01
    Get full text
    Article
  3. 3
    Rapid initiation of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in acute and early HIV-1 infection: a DIAMOND subgroup analysis

    Rapid initiation of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in acute and early HIV-1 infection: a DIAMOND subgroup analysis by Keith Dunn, Rachel Rogers, Richard Bruce Simonson, Donghan Luo, Shubin Sheng, Purnima T. Kassam, Sareh Seyedkazemi, Hélène Hardy

    Published 2021-07-01
    Get full text
    Article

Search Tools: